

IN THE CLAIMS

Please cancel claims 1-16, without prejudice.

Please add the following new claims:

- A cont'd -*
17. (new) A chimeric parainfluenza virus comprising:
(i) nucleotide sequences of a Kansas-strain bovine parainfluenza virus type 3 genome; and
(ii) one or more heterologous sequences, wherein said one or more heterologous sequences have been added to said virus genome or have been substituted for nucleotide sequences of said virus genome.
18. (new) The chimeric parainfluenza virus of claim 17, wherein the heterologous sequences are that of a human parainfluenza virus.
19. (new) The chimeric parainfluenza virus of claim 18, wherein the heterologous sequences encode the F and HN glycoproteins of a human parainfluenza virus.
20. (new) The chimeric parainfluenza virus of claim 19, wherein the F and HN glycoproteins of an hPIV are that of a human parainfluenza virus type 3.
21. (new) The chimeric parainfluenza virus of claim 17, wherein the heterologous sequences are that of an influenza virus or of a respiratory syncytial virus.
22. (new) The chimeric parainfluenza virus of claim 17, wherein the Kansas-strain bPIV3 backbone contains mutations or modifications, in addition to heterologous sequences, which result in a chimeric virus having a phenotype more suitable for use in vaccine formulations such as an attenuated phenotype or a phenotype with enhanced antigenicity.
23. (new) A chimeric parainfluenza virus comprising:
(i) the genome of Kansas-strain bovine parainfluenza virus type 3; and

(ii) one or more heterologous sequences, wherein said one or more heterologous sequences have been added to said backbone.

24. (new) The chimeric parainfluenza virus of any one of claims 17-23, wherein said heterologous sequence substitutes both the F and the HN gene of Kansas-strain bovine parainfluenza virus type 3.

25. (new) The chimeric parainfluenza virus of any one of claims 17-23, wherein said heterologous sequence is added at a nucleotide position of Kansas-strain bovine parainfluenza virus type 3 selected from the group consisting of nucleotide position 5041, the HN gene, and nucleotide position 8529.

REMARKS

A new set of informal Drawings has been submitted to replace the originally submitted set of Drawings, which was objected to by the Draftsperson due to poor quality (half-tone) and illegible numbers and reference characters. Applicants believe that the submission of the new set of Drawings submitted concurrently herewith overcomes this objection.

Claims 1-16 have been canceled without prejudice. Applicants reserve the right to prosecute the subject matter of the canceled claims in one or more continuation, continuation-in-part, or divisional application. New claims 17-25 have been added. The new claims are fully supported by the disclosure as originally filed, see, *e.g.*, the table below, and do not represent new subject matter.

<u>CLAIM</u>	<u>SUPPORT IN THE SPECIFICATION</u>
17	page 6, lines 24-32
18-20	page 7, lines 14-17
21	page 27, lines 21-26
22	page 6, line 32 to page 7, line 3
23	page 6, lines 24-32
24, 25	Example 6, page 30, line 8 to page 31, line 13